Sees FY23 Insurance MCR is expected to be in the range of 83% – 85% in 2023; Non-Insurance revenue is expected to be in the range of $0.75 billion to $0.80 billion in 2023; Non-Insurance MCR is expected to be in the range of 98% – 100% in 2023; Adjusted SG&A is expected to be between $315 million and $325 million; Adjusted EBITDA is expected to be between ($70 million) and ($120 million).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLOV:
- Clover Health Reports Strong Second Quarter 2023 Results; Highlights Improved Financial Performance and Guidance Ranges
- Clover Health options imply 16.3% move in share price post-earnings
- Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement
- Clover Health to Present at Canaccord Genuity 43rd Annual Growth Conference and 2023 Wells Fargo Healthcare Conference
- Clinician Use of Clover Assistant is Associated with Significant Improvement in the Early Identification and Management of Chronic Kidney Disease
